Active, not recruitingPhase 2NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Zilovertamab vedotin(biological)
- Enrollment
- 223 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska, United States
- Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona, United States
- Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona, United States
- University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008), Aurora, Colorado, United States
- Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois, United States
- University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038), Fairway, Kansas, United States
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky, United States
- Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland, United States
- Tufts Medical Center ( Site 0024), Boston, Massachusetts, United States
- Massachusetts General Hospital ( Site 0018), Boston, Massachusetts, United States
- Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts, United States
- University of Michigan ( Site 0009), Ann Arbor, Michigan, United States
- Henry Ford Hospital ( Site 0035), Detroit, Michigan, United States
- Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York, United States
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05458297 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn